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Craig R. ReinemeyerThis special issue of Veterinary Parasitology contains a
omprehensive collection of applied papers which report
he  results of 40 clinical trials conducted in four countries
n  two continents. The common focus of these articles
s  a novel anthelmintic formulation for beef cattle, Epri-
omectin Extended-Release Injectable. As reported herein,
his  product has unique pharmacologic properties that
rovide long-acting therapeutic and prophylactic efﬁcacy
gainst a broad spectrum of nematode and arthropod
arasites. These features deliver excellent parasite con-
rol  without the need to handle cattle frequently, thereby
nhancing economic returns in a variety of beef manage-
ent systems.
This  collection elicits fond memories of the golden age
f  pharmaceutical development of cattle anthelmintics.
uring the 1980s and 1990s, commercialization of the
vermectin and milbemycin classes of anthelmintics ini-
iated  numerous ﬁeld trials, generated reams of real-world
ata, and revived an interest in applied parasitology. On the
cademic  side, the launches of these compounds spawned
ocused scientiﬁc symposia and special issues for publica-
ion,  fostered international collaborations, and stimulated
mplementation of the epidemiologic approaches to para-
ite  control championed by Drs. Jimmy  Armour, J.F. Michel,
upert  Herd, Jimmy  Williams, and so many other luminar-
es  of applied bovine parasitology.
When  development of Eprinomectin ERI began nearly
 decade ago, bovine anthelmintic resistance was a rela-
ive  novelty that had only been observed in Cooperia spp.
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putative resistance to macrocyclic lactone anthelmintics
has also been reported in populations of Cooperia and
Haemonchus in North and South America. Surprisingly few
details  are known about selection for this problem (e.g.,
role  of formulations and routes of administration) or its
impact  on health and productivity. However, it is undeni-
able  that further elucidation of this issue will signal the
demise of rote, unmonitored use of anthelmintics, at least
by  progressive producers and veterinarians. As summa-
rized herein by Andy Forbes, bovine anthelmintic use in
the  future will need to be combined with efﬁcacy moni-
toring, maintenance of refugia, and exploitation of climatic
and  management conditions to achieve effective and sus-
tainable  parasite control.
Novel  pharmaceutical products like Eprinomectin ERI
represent not only just new tools, but also agents of
change for the cattle industry. But, safe and effective drugs
only  constitute a partial solution unless accompanied by
practical  education and scientiﬁc evidence to support man-
agement  decisions in the ﬁeld. This admirable collection of
papers  is a positive step in that direction.
Guest EditorPresident, East Tennessee Clinical Research,
Inc. Rockwood, TN 37854, United States
E-mail address: crr@easttenncr.com
